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OBJECTIVES We compared the prevalence and extent of coronary artery calcium (CAC) among persons
with the metabolic syndrome (MetS), diabetes, and neither condition.
BACKGROUND The prevalence and extent of CAC has not been compared among those with MetS, diabetes,
or neither condition.
METHODS Of 1,823 persons (36% female) age 20 to 79 years who had screening for CAC by computed
tomography, 279 had MetS, 150 had diabetes, and the remainder (n  1,394) had neither
condition. Metabolic syndrome was defined with 3 of the following: body mass index 30
kg/m2; high-density lipoprotein cholesterol 40 mg/dl if male or 50 mg/dl if female;
triglycerides 150 mg/dl; blood pressure 130/85 mm Hg or on treatment; or fasting
glucose 110 to 125 mg/dl. The prevalence and odds of any and significant (75th percentile)
CAC among these groups and by number of MetS risk factors were determined.
RESULTS Those with neither MetS nor diabetes, MetS, or diabetes had a prevalence of CAC of 53.5%,
58.8%, and 75.3% (p  0.001), respectively, among men and 37.6%, 50.8%, and 52.6% (p 
0.001), respectively, among women. Coronary artery calcium increased by the number (0 to
5) of MetS risk factors (from 34.0% to 58.3%) (p 0.001). Forty-one percent of subjects with
MetS had either a20% 10-year risk of CHD or CAC75th percentile for age and gender.
Risk factor-adjusted odds for the presence of CAC were 1.40 (95% confidence interval [CI]
1.05 to 1.87) among those with MetS and 1.67 (95% CI 1.12 to 2.50) among those with
diabetes, versus those with neither condition.
CONCLUSIONS Those with MetS or diabetes have an increased likelihood of CAC compared with those
having neither condition. (J Am Coll Cardiol 2003;41:1547–53) © 2003 by the American
College of Cardiology Foundation
The metabolic syndrome (MetS) is characterized by insulin
resistance and a clustering of cardiovascular risk factors that
includes: hypertension; obesity; hypertriglyceridemia; the
presence of small, dense low-density lipoprotein (LDL); a
low level of high-density lipoprotein (HDL) cholesterol;
and hypercoagulabity (1). Metabolic syndrome has also
contributed greatly to the worldwide epidemic of type 2
diabetes. The final products of this syndrome are endothe-
lial dysfunction, atherosclerosis, and cardiovascular disease
(2). It has recently been estimated that about 47 million
U.S. residents have MetS (including those with diabetes),
corresponding to 22% of men and 24% of women age 20
years and above (3). In addition, it has been demonstrated
that individuals with this condition are at a three-fold
greater risk of coronary heart disease (CHD) and stroke,
and more than a five-fold greater risk of cardiovascular
mortality (4). In addition, MetS has recently been shown to
be related to an increased risk of subclinical ischemic heart
disease, as determined by resting electrocardiogram criteria
(5). There have been no published reports examining the
relation of MetS to subclinical coronary atherosclerosis
among middle-age men and women without clinically
documented CHD. Studies involving assessment of coro-
nary artery calcium (CAC), an indicator of the presence and
burden of atherosclerosis, have previously shown the prev-
alence of CAC to be significant in persons with diabetes
(6,7), and that CAC is highly sensitive for detecting those
with clinical coronary disease among persons with type 1
diabetes (6). In large samples of primarily nondiabetic
high-risk asymptomatic individuals, a relation of higher
levels of CAC to future risks of CHD events has been
widely reported (8–11), although the magnitude of risk
associated with a given level of CAC remains controversial.
In this report, we examine the prevalence of CAC, an
indicator of subclinical coronary atherosclerosis, among
persons with MetS (but without diabetes), diabetes, and
neither condition. The comparative likelihood of more
advanced disease as evidenced by higher levels of CAC was
also explored among the groups studied.
METHODS
We examined clinical characteristics of 1,823 persons age 20
to 79 years, free of known clinical CHD, who underwent
CAC scanning by an Imatron C-150 (Imatron Inc., South
San Francisco, California) electron beam tomographic scan-
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ner during 1999 to 2001 at Cedars-Sinai Medical Center.
Subjects were self-referred, referred by their physician, or
recruited as part of ongoing research protocols. The current
study was approved by the Cedars-Sinai Medical Center
Institutional Review Board (IRB #3354). The imaging
protocol involved an experienced licensed radiologic tech-
nician acquiring a single scan on each patient, consisting of
approximately 30 to 40 3-mm slices sufficient to scan the
entire heart, done at 50% electrocardiogram triggering in an
attempt to minimize motion artifact. Breath-holding in-
structions were also given to minimize misregistration. Foci
of coronary artery calcification were identified and scored by
an experienced technician, using semiautomatic commercial
software (ScImage, Inc., Los Altos, California), and the
scoring was verified by an imaging cardiologist. The soft-
ware initially calculated lesion-specific scores as the product
of the area of each calcified focus and peak computerized
tomography number (scored as 1 if 131 to 199 Hounsfield
units [HU], 2 if 200 to 299 HU, 3 if 300 to 399 HU, and
4 if 400 HU or greater). These were summed across all
lesions identified within left main, left anterior descending,
left circumflex, and right coronary arteries to provide
arterial-specific calcium scores, and across arteries to provide
a total Agatston calcium score used for analysis in this report
(10).
A fasting lipid profile (total cholesterol, HDL choles-
terol, and triglycerides, with calculated LDL cholesterol)
plus glucose was performed on each study participant by a
Cholestech (Hayward, California) desktop chemical ana-
lyzer. Two readings of blood pressure (with mean systolic
and diastolic readings used for analysis) and weight and
height for calculation of body mass index (BMI) (weight in
kg/height squared in meters) were also obtained at the same
visit. A brief medical history to assess prior history of cardiac
disease, diabetes, and medication usage was also taken.
Diabetes was defined as a self-reported history of being told
by a physician that diabetes was present or having a fasting
glucose of 126 mg/dl or greater.
The presence of MetS was determined by criteria as
defined by the Third Adult Treatment Panel (ATP) of the
National Cholesterol Education Program (NCEP) (1),
modified to use BMI instead of waist circumference cut-
points. Therefore, this required subjects to have three of the
following criteria: 1) BMI of 30 kg/m2 or greater (in lieu of
using ATP waist circumference cutpoints, as waist circum-
ference measures were not available in our study sample); 2)
serum triglycerides of at least 150 mg/dl; 3) HDL choles-
terol levels of40 mg/dl in men and50 mg/dl in women;
4) impaired fasting glucose of 110 to 125 mg/dl; or 5) blood
pressure of at least 130/85 mm Hg or treated hypertension.
A recently published analysis of the Third National Health
and Nutrition Examination Survey showed a high concor-
dance of obesity at or above our BMI cutpoint and a high
waist circumference as defined by NCEP III criteria (12),
lending support to the validity of our measure.
Initially, age, gender, and risk factor distributions were
compared among those without disease, those defined with
the MetS, and those with diabetes, using the chi-square test
of proportions for categorical risk factors and analysis of
covariance (adjusted for age and gender) for comparing
levels of continuous risk factors. The prevalence of coronary
calcium (percent with positive scores 0), as well as the
prevalence of coronary calcium at or above the 75th percen-
tile for age and gender (as determined by data on a large
sample of men and women programmed into the ScImage
database) (13), were compared between disease groups, as
well as by number of metabolic risk factors as described
above (0 to 5). The 75th percentile has been suggested as a
criterion for significant coronary calcium warranting more
aggressive risk factor intervention (14). We also examined
the proportion of individuals with MetS who achieved a
20% estimated 10-year risk of CHD based on Framing-
ham risk score algorithms (1) or CAC 75th percentile as
another means to estimate the proportion of such subjects
that may warrant aggressive risk factor modification. Logis-
tic regression presented the odds of CAC (any CAC and
CAC at or above the 75th percentile to indicate significant
CAC) in those with MetS or diabetes in comparison to
those with neither condition (with 95% confidence interval
[CI] also presented), initially age- and gender-adjusted, and
then adjusted additionally for total cholesterol, reported
cholesterol-lowering medication (because of its relation to
both disease status and CAC), and cigarette smoking
(because other risk factors such as HDL cholesterol and
systolic blood pressure were included in the definition of
MetS, they were not adjusted for in these models). Separate
models were also run where subjects classified as having
neither MetS nor diabetes, but who had two MetS risk
factors and indicated they were on lipid-lowering therapy,
were censored (n 96, of which 68 were positive for CAC);
these individuals were among those most likely to have been
classified as having MetS had they not been on lipid-
lowering therapy.
RESULTS
In our study, 279 persons (15%) were defined as having
MetS and 150 persons (8%) met the definition for diabetes
out of the total sample of 1,823 persons. Table 1 shows a
Abbreviations and Acronyms
ATP  Adult Treatment Panel
BMI  body mass index
CAC  coronary artery calcium
CHD  coronary heart disease
CI  confidence interval
HDL  high-density lipoprotein
HU  Hounsfield units
LDL  low-density lipoprotein
MetS  metabolic syndrome
NCEP  National Cholesterol Education Program
OR  odds ratio
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significant difference in all coronary risk factors between
those without disease, those with MetS, and those with
diabetes. Those with MetS were less likely to be women
(24%); were younger (mean age 52.7 years) compared with
the other groups; had the highest levels of BMI (mean 30.2
kg/m2), triglycerides (mean 238.5 mg/dl), total cholesterol
(mean 215.8 mg/dl), and diastolic blood pressure (mean
82.2 mm Hg); and had the lowest levels of HDL cholesterol
(39.5 mg/dl). In those with MetS, systolic blood pressure
(mean 142.9 mm Hg) was similar to those with diabetes,
but significantly higher (p  0.0001) than in those with
neither condition.
Overall, 57% of persons with the MetS had coronary
calcium, compared with 67% of those with diabetes and
47% of those with neither condition (p  0.0001). The
prevalence of CAC in women with MetS was 51%, similar
to those with diabetes (53%), but higher than those with
neither condition (38%) (p  0.02). In men, the prevalence
of CAC in those with MetS was 58%, compared with 75%
in those with diabetes and 54% in those with neither
condition (p  0.0007) (Fig. 1). Among men, 25% of those
with MetS had CAC at or above the 75th percentile,
compared with 41% of those with diabetes and 21% of those
with neither condition (p  0.0001). For women, these
figures were 25%, 30%, and 20%, respectively (p  0.21)
(Fig. 1). There was also a graded association between the
prevalence of CAC and the number of metabolic risk factors
(excluding persons with diabetes) (Fig. 2). Coronary artery
calcium prevalence ranged from 34% in those without any
metabolic risk factors to 50%, 56%, 54%, 63%, and 58% in
those with one, two, three, four, and five metabolic risk
factors, respectively (trend p 0.001). For the prevalence of
Table 1. Prevalence and Mean (SD) Levels of Baseline Characteristics by Presence of Metabolic
Syndrome, Diabetes, or Neither Condition (n  1,823)
Neither Condition
(n  1,394)
Metabolic Syndrome
(n  279)
Diabetes
(n  150) p Value
Female (%) 38.7 24.0 38.0  0.0001
Age (yrs) 53.4  9.8 52.7  9.9 57.2  9.1  0.0001
Glucose (mg/dl)* 94.6  17.7 98.5  17.7 140.1  17.9  0.0001
BMI (kg/m2)* 25.1  4.1 30.2  4.1 29.0  4.2  0.0001
Triglycerides (mg/dl)* 106.1  109.6 238.5  109.7 209.6  110.5  0.0001
Total cholesterol (mg/dl)* 206.1  41.4 215.8  41.5 202.7  41.8  0.0007
HDL cholesterol (mg/dl)* 58.5  16.6 39.5  16.6 49.4  16.7  0.0001
Systolic BP (mm Hg)* 132.3  17.5 142.9  17.5 141.6  17.8  0.0001
Diastolic BP (mm Hg)* 76.1  10.6 82.2  10.6 79.2  10.7  0.0001
*Adjusted for age and gender.
BMI  body mass index; BP  blood pressure; HDL  high density lipoprotein.
Figure 1. Prevalence of coronary artery calcium (CAC) by disease category and gender. Gray bars neither condition; striped bars metabolic syndrome
(MetS); black bars diabetes. p 0.0002 for men and p 0.02 for women for any CAC and p 0.01 for men and p 0.19 for women for CAC75th
percentile across groups (MetS, diabetes, and neither condition).
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CAC 75th percentile, the respective figures were 15%,
22%, 24%, 23%, 33%, and 25% (trend p  0.001) (Fig. 2).
Of those with MetS, 21% of such individuals had 20%
Framingham calculated risk of CHD over 10 years (defined
by ATP as a CHD “risk equivalent”; 25% had CAC scores
at or above the 75th percentile (based on age and gender),
and 41% had one or both characteristics (Fig. 3).
From logistic regression analyses, the odds ratio (OR) of
CAC (compared with those with neither condition) was
significantly higher among those with MetS (OR 1.45, 95%
CI 1.09 to 1.94) or diabetes (OR 1.67, 95% CI 1.12 to
2.48). Additional adjustment for total cholesterol, lipid-
lowering medication use, and cigarette smoking (risk factors
not among those defining MetS) showed these relations to
persist (OR 1.40, 95% CI 1.05 to 1.87 for MetS and OR
1.67, 95% CI 1.12 to 2.50 for diabetes) (Table 2). In
predicting the presence of significant CAC (75th percen-
tile), diabetes bore a stronger relation (OR 2.01, 95% CI
1.40 to 2.89), but findings regarding the likelihood of
significant CAC in persons with MetS were attenuated (OR
1.29, 95% CI 0.95 to 1.75), with similar findings after
additional adjustment for total cholesterol, lipid-lowering
medication, and smoking (Table 2). In separate models
where those on lipid-lowering medication who had neither
MetS nor diabetes (but had two MetS risk factors) were
censored, increased age-, gender-, and risk factor-adjusted
odds for CAC in those with MetS (OR 1.7, 95% CI 1.3 to
2.3) and diabetes (OR 2.3, 95% CI 1.5 to 3.3) (as compared
with those having neither condition) were observed. Anal-
ysis for predicting the presence of CAC at or above the 75th
percentile similarly resulted in increased adjusted odds for
CAC in those with MetS (OR 1.5, 95% CI 1.1 to 2.0) and
diabetes (OR 2.5, 95% CI 1.7 to 3.6) (as compared to those
with neither condition).
DISCUSSION
Our results suggest a high prevalence of subclinical coronary
atherosclerosis, as evidenced by CAC, an aspect of athero-
sclerosis, among both men and women defined to have
Figure 2. Prevalence of coronary artery calcium (CAC) and significant CAC (75th percentile) by number of metabolic syndrome risk factors. Striped
bars  present; black bars  CAC 75th percentile. p  0.0001 for CAC present and p  0.0002 for CAC 75th percentile for test of trend across
number of metabolic risk factors for CAC present and for CAC 75th percentile.
Figure 3. Proportion of persons identified with the metabolic syndrome classified by presence of 20% 10-year estimated risk of coronary heart disease
(CHD) and significant coronary artery calcium (CAC) (75th percentile). Striped bar  CAC 75th percentile; gray bar  10-year CHD risk 20%;
black bar  either or both.
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MetS. Several studies have documented an increased risk of
CHD associated with CAC in subjects with multiple risk
factors (8–11), although the magnitude of risk associated
with a given level of calcium varies from study to study, and
whether CAC predicts CHD events independent of care-
fully measured risk factors remains controversial. Moreover,
the relation of CAC to clinical events in persons with MetS
is unknown.
In our study, women with MetS have a prevalence of
CAC as high as women with diabetes, despite age being
similar (whereas the higher prevalence of coronary calcium
among men with diabetes compared with those with MetS
may be partially due to the greater age among those with
diabetes). In addition, there was a graded association be-
tween the number of metabolic risk factors and coronary
calcium. The increased likelihood and extent of CAC in
persons with MetS, as compared with normal persons, is
largely explained by cardiovascular risk factors that comprise
the definition of MetS, namely HDL cholesterol, which is
significantly lower among those with MetS. Although the
odds of any calcium were significantly higher both in
persons with MetS and those with diabetes, findings re-
garding the relation to significant calcium (75th percentile
or greater) showed only diabetes to remain predictive in our
primary, uncensored analyses (but MetS did remain mod-
estly associated with significant CAC in censored analyses).
This suggests that although earlier atherosclerosis is more
common among both those with MetS and diabetes, more
advanced atherosclerosis as evidenced by greater levels of
coronary calcium is most apparent in those with diabetes.
Current estimates are that approximately 47 million
adults in the United States would be defined to have the
MetS on the basis of the most recent definition as recom-
mended by NCEP-ATP III (1). Although such persons do
have lower levels of HDL cholesterol and higher levels of
total cholesterol and systolic blood pressure, traditional
components of the Framingham risk equations, nontradi-
tional Framingham risk factors such as BMI (or central
obesity) and triglyceride levels are markedly higher in these
individuals, and are similar to those who have clinical
diabetes. In fact, in our study sample, we show levels of
triglycerides and total cholesterol to be significantly higher,
and HDL cholesterol significantly lower in those defined to
have the MetS compared to diabetes.
Both the NCEP (1) and the American Diabetes Associ-
ation (15) recommend aggressive risk factor management of
persons with clinically defined diabetes on par with second-
ary prevention guidelines for cardiovascular disease manage-
ment. This includes treatment of elevated LDL cholesterol,
if present, to a goal of 100 mg/dl, and even more
aggressive blood pressure goals to 130 mm Hg systolic
and 80 mm Hg diastolic blood pressure. Moreover, those
with a 20% 10-year Framingham estimated risk of CHD
are considered CHD risk-equivalents warranting lipid treat-
ment according to secondary prevention guidelines (1), and
those with CAC scores 75th percentile have also been
recommended for more aggressive treatment (14). Although
these reports do not give specific goal levels for risk factors
in persons with the MetS that are distinct from others with
multiple risk factors, our report estimates approximately
20% of those with MetS have an estimated Framingham
10-year risk of CHD of 20%, 25% have coronary calcium
levels in the highest quartile, and 41% have one or both
characteristics. These findings suggest that screening results
for subclinical disease (such as by coronary calcium detec-
tion) in patients with MetS may identify a substantial
number of additional individuals for whom more aggressive
risk factor intervention might be warranted.
Recently, the American Heart Association Prevention V
conference (16) has suggested that persons at intermediate
CHD risk based on known risk factors may be candidates
for screening of CAC by computed tomography. An up-
coming Bethesda Report from the American College of
Cardiology due to be released in 2003 will provide further
guidance into the appropriate use of noninvasive testing for
atherosclerosis in asymptomatic persons, including specifi-
cally what constitutes sufficient CHD risk potentially war-
ranting such testing. Considering that the NCEP (1)
considers those at 10% to 20% estimated risk of CHD to be
at intermediate risk, many persons with MetS would be
Table 2. Multivariable Analysis of CAC and Disease Status
Neither Condition Metabolic Syndrome Diabetes
Age- and gender-adjusted
(n  1,823)
Odds of CAC present 1.0 (referent) 1.44 (1.08–1.93) p  0.01 1.71 (1.14–2.54) p  0.009
Odds of CAC 75th
percentile
1.0 (referent) 1.28 (0.94–1.72) p  0.12 2.10 (1.47–3.01) p  0.0001
Adjusted for age, gender, total
cholesterol, cholesterol-
lowering medication, and
cigarette smoking
(n  1,818)
Odds of calcium present 1.0 (referent) 1.40 (1.05–1.87) p  0.02 1.67 (1.12–2.50) p  0.01
Odds of CAC 75th
percentile
1.0 (referent) 1.25 (0.92–1.71) p  0.16 2.03 (1.41–2.92) p  0.0001
CAC  coronary artery calcium.
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suitable candidates for such noninvasive testing if this
definition were to be adopted.
Study limitations. Given that our cohort is composed
primarily of self-referred volunteers, it is possible our sample
identified with MetS is not entirely representative of those
in the general population. We report, however, a similar
combined prevalence of MetS (15%) and diabetes (8%)
(total 23%) to that been reported previously in U.S. adults
(24%) (3).
As we utilized measures of BMI instead of waist circum-
ference, which were not available, it is possible we may have
misclassified some individuals that would have been classi-
fied differently based on waist circumference measures that
constitute the accepted criterion for MetS (1). However, in
a recently published report (11) among adults in the Third
National Health and Nutrition Examination Survey showed
the vast majority of individuals with a BMI 30 kg/m2 also
had a high waist circumference as defined by NCEP criteria,
lending support to our revised definition; moreover, 97% of
those we identify with MetS (incorporating BMI instead of
waist circumference) would have also been identified by the
definition using waist circumference, and of those we do not
identify with MetS, 96.5% would not have been identified
by the NCEP definition (unpublished data). This high
correspondence in definitions may be due to many individ-
uals with either increased BMI or waist circumference
having the same accompanying MetS risk factors such as
elevated triglycerides, low HDL cholesterol, and increased
blood pressures. This provides reasonable certainty as to the
robustness of our definition. Also, other published defini-
tions (2,4,5,17) vary more markedly from the NCEP defi-
nition, making comparability to the NCEP definition more
difficult to establish.
Finally, because some individuals with neither MetS nor
diabetes (especially those borderline for being defined as
MetS—for example, with two but not three MetS risk
factors) who were on lipid-lowering therapy might have
been classified as having MetS if they were not on therapy,
our uncensored analysis may have underestimated the rela-
tion of MetS or diabetes with CAC. Censoring these
individuals does result in higher ORs (significant for both
any CAC and for CAC 75th percentile) associated with
MetS or diabetes. This suggests that if such misclassifica-
tion were present among these individuals, accounting for
this would have increased the strength of our associations.
However, as these results are somewhat speculative, our
uncensored analysis remains most conservative.
Conclusions. Our study demonstrates that individuals
with MetS have a higher likelihood and prevalence of CAC
than patients without MetS. Moreover, those with diabetes
have an increased likelihood of having significant CAC.
The presence of MetS indicates a moderately increased
likelihood for subclinical disease. Although the extent of
subclinical atherosclerosis (for example, with CAC as an
aspect of atherosclerosis) may not be as significantly ad-
vanced as in persons with diabetes, the mere presence of
such disease may be a potent motivator of lifestyle changes
and improved compliance to risk-reducing medical therapy,
as we have previously suggested (18). Further study in
larger, prospective cohorts (including the Early Identifica-
tion of Subclinical Atherosclerosis Using Noninvasive Re-
search [EISNER] study currently being performed at
Cedars-Sinai Medical Center) will provide further informa-
tion on this issue. In addition, it will be important to
determine whether individuals with MetS or diabetes, but
who additionally have subclinical disease, may identify a
subset at greater risk of future cardiovascular events. The
ongoing National Institutes of Health Multiethnic Study of
Atherosclerosis (MESA) (19) will provide further insight
into these and other questions among high-risk individuals
with multiple risk factors, including those with MetS and
diabetes.
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